Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Author's Avatar
Mar 31, 2023

FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024